microRNA as a therapeutic for ischemic stroke

microRNA (miRNA) are important regulators of gene expression. miRNA have the potential as a treatment to modulate genes, pathways and cells involved in ischemic stroke. In this review, we specifically present miRNA in stroke as a treatment to decrease thrombosis, reduce blood brain barrier (BBB) disruption and hemorrhagic transformation (HT), modulate inflammation, and modify angiogenesis. miRNA as a treatment for stroke is an emerging area with evidence from animal studies demonstrating its potential. While no miRNA is currently approved for human use, several have shown promise in clinical trials to treat medical conditions, such as miR-122 for hepatitis C. The role of miRNA as a treatment for specific applications in ischemic stroke is presented including a discussion of the benefits and barriers of miRNA as a treatment, and directions for future advancement.

Automated summary

microRNA (miRNA) regulates gene expression and has the potential to be used as a treatment for ischemic stroke. This review focuses on the role of miRNA in reducing thrombosis, blood brain barrier disruption, hemorrhagic transformation, inflammation, and angiogenesis. Although no miRNA has been approved for human use yet, clinical trials have shown promising results in treating conditions such as hepatitis C. The benefits, barriers, and future directions of using miRNA as a treatment for ischemic stroke are also discussed.